Introduction
Expanded insight into the cellular pathologies of cancers and viruses has made it apparent that neoplasia and viral infection often result in remarkably similar alterations to cell biology. In the course of their life cycle, many viruses transform previously healthy cells to create a cellular environment more complementary to viral replication. Oftentimes, the cellular pathways targeted by viruses for disruption are also disrupted in the course of neoplastic transformation. This suggests that by exploiting the properties that lead to a cancerous state, some viruses can preferentially kill tumor cells. Deliberate infection of individuals with wild-type viruses, however, raises significant safety concerns (Ward et al., 1955; Bell et al., 1956; Mitsui et al., 1957; Huneycutt et al., 1993; Stojdl et al., 2000) . Therefore, many groups have developed attenuated derivatives of wild-type viruses specific for tumors by regulating those viral mechanisms necessary for infection of healthy cells and systems but dispensable for productive infection of tumors.
Selectively replicating oncolytic adenoviruses are among the more prevalent and best-studied families of this class of therapeutics. To date, the tropism of adenovirus-derived oncolytic agents has been successfully redirected towards cancer cells by artificially introducing greater functional overlap of viral and neoplasia-associated mechanisms. With the subset of transcriptionally regulated adenoviruses, that redirection is mediated by placing key viral genes under heterologous control of promoters, enhancers, and silencers of transcriptionally activated tissue or tumorassociated markers (Rodriguez et al., 1997; Yu et al., 1999b; Li et al., 2001; Johnson et al., 2002; Jakubczak et al., 2003; Ryan et al., 2004) . Generally, the cis-acting cellular promoter, enhancer, and/or silencer of a transcriptionally upregulated marker is inserted downstream, or in place of, the endogenous promoter for an essential viral transcription unit such as E1a, E1b, or E4. The heterologous promoter is then expected to be transactivated by the same transcription factors and complexes that drive transcriptional upregulation of the marker. Therefore, expression of the regulated viral transcription unit is predicted to occur in a fashion specific to tissues or tumors expressing or overexpressing the marker. The result has been the development of many intriguing therapeutic candidates, some of which have been administered in the clinic (Table 1) . To date, the safety profile of this class of agents has been encouraging. Additionally, some biological activity has been demonstrated, particularly when administered in combination with chemotherapeutics and/or radiation.
Improving the therapeutic potential of such agents requires a better understanding of adenovirus and tumor biology, two fields that should advance rapidly as better diagnostic and analytical tools become available.
Additionally, much effort is currently being focused on enhancing the efficacy of adenovirus-based vectors by arming them with transgenes and/or targeting vectors by genetically or chemically modifying the viral capsid, but significant scientific and clinical obstacles remain. Still, transcriptionally regulated adenoviruses offer, as a platform, considerable adaptability that may allow for future viruses that more fully exploit the convergence of neoplasia and virally associated cellular pathologies.
This review focuses on evaluating strategies by which adenoviruses can be transcriptionally targeted to tumors, considers the limitations of current strategies and discusses possibilities for future improvements. For in-depth discussions of other families of oncolytic agents or the broader field of selectively replicating adenoviruses, readers are referred to the following sources (Kirn, 2000; Reid et al., 2002; Varghese and Rabkin, 2002; Giedlin et al., 2003; Wakimoto et al., 2003) .
Adenovirus biology and selectively replicating adenoviruses
Several points in the adenoviral life cycle can be exploited to target replication to desired tissues. Briefly, wild-type adenovirus serotype 5 (Ad5), the serotype upon which most oncolytic adenoviruses are based, is a double-stranded, nonenveloped DNA virus of approximately 36 000 base pairs. Ad5 vectors can replicate efficiently at roughly 105% of the wild-type genome size (approximately 3000 extra base pairs) (Bett et al., 1993) . Additionally, several adenoviral genes can be removed with varying consequences to the replicative capacity of the virus. The adenoviral life cycle is a regulated cascade of events divided into early and late phases (before and after viral DNA replication, respectively). Transcripts are encoded via alternative splicing of each transcription unit to generate multiple products from each region (Berget et al., 1977; Berk and Sharp, 1978) . Many of the early phase region (E1, E2, E3, and E4) products are necessary for downstream events in the cascade and progression to late phase transcription. Additionally, a number of the most critical early transcript functions (such as cell cycle deregulation and inhibition of apoptosis) are often complemented by the deregulated states associated with tumor cell differentiation (Yew and Berk, 1992; Lukas et al., 1994; Han et al., 1998) . Theoretically, these points within the adenoviral life cycle may be regulated to limit adenoviral replication preferentially to tumor cells.
Gene products of the E1 region are expressed earliest in the viral life cycle and are critical for virus-mediated transformation of healthy cells and transactivation of other viral genes. (For an in-depth discussion of these properties, readers are referred to Berk, 2005, this publication .) The E1 region is divided into two transcription units, E1a and E1b. The E1a unit encodes proteins that, in essence, prime the cell and the virus for the adenovirus life cycle. With respect to the cell, the 
Oncolytic adenoviruses D Ko et al conserved CR2 region of the E1a proteins binds the retinoblastoma protein (pRb) promoting an increase in free E2F and deregulation of the cell cycle (Ikeda and Nevins, 1993) . With respect to the virus, the E1a proteins act as transactivators for other adenoviral regions, including E1b, E3, E4, and the major late promoter (Berk et al., 1979; Nevins, 1981; Sellers et al., 1995) . E1a expression, however, also results in the activation of cellular stress response mechanisms and eventual apoptosis (Rao et al., 1992) . One of the major functions of the E1b proteins is to counteract apoptosis. The 19 kDa subunit of E1b (E1b 19 kDa) acts as a Bcl2 analog to prevent mitochondrial release of cytochrome c and activation of caspase 8 (Rao et al., 1992) . Similarly, the 55 kDa subunit of E1b (E1b 55 kDa) binds p53 and inactivates it, thereby preventing p53-induced apoptosis (Sarnow et al., 1982; Jenkins et al., 1984; Yew and Berk, 1992) . Since many of these critical functions of the E1a and E1b proteins are complemented in tumor cells, regulating these transcription units can result in selective viral replication in tumor cells. Products of the E4 transcription unit are similarly critical to the viral life cycle. Many of the functions of E4 proteins are complementary, supplementary, or inhibitory to the functions of E1a and E1b proteins. For example, E4 orf1 and E4 orf4 interact with the molecular target of rapamycin to stimulate entry into S-phase (O'Shea et al., 2005) . Additionally, E4 orf6 complexes with E1b 55 kDa to regulate nuclear export of viral and cellular mRNA (Dobbelstein et al., 1997) . In contrast, binding of E4 orf4 to protein phosphatase 2A results in hyperphosphorylation of selected transcription factors, including the E1a proteins, which results in an inhibitory effect on E1a-induced transcription of other viral transcription units (including the E4 region itself) (Obert et al., 1994) . Thus, regulation of E4 expression is another point in the viral life cycle with the potential to provide selective replication in tumor cells.
One way to regulate the expression of regions such as E1a, E1b, or E4 is to introduce deletions to the viral genome resulting in loss of function mutants that preferentially replicate in and lyse complementary tumor cells as opposed to healthy cells. For example, the E1b 55 kDa mutant Addl1520 (Onyx-015) was originally thought to replicate in cells with inactivated p53 (Barker and Berk, 1987; Bischoff et al., 1996) . Recent studies have suggested an alternative mechanism for selective replication in which Addl1520 replicates in cells that complement the viral mRNA export mechanism of E1b 55 kDa (O'Shea et al., 2004) . Whether complemented by p53 inactivation or an mRNA export mechanism, selective replication in cells complementary to the loss of function mutation illustrates the potential of functional overlaps.
While adenoviral derivatives have been developed to take similar advantage of other functional overlaps, another strategy is to engineer specificity by transcriptionally regulating key early transcription units. Use of the regulatory machinery for tissue-specific markers such as the prostate-specific antigen (PSA) to drive transcription of essential viral genes can lead to viral replication largely restricted to marker-associated tissues and significantly enhanced in tumor cells overexpressing PSA. Taking that approach one step further, similar applications of the regulatory machinery for tumor-specific markers, such as E2F or human telomerase reverse transcriptase (hTERT) should lead to viral replication largely restricted to tumors. Such a strategy allows for an adaptable platform, limited at a cellular level primarily by the availability of appropriate transcriptional regulatory elements (TRE). That is, one must identify TREs that are strong enough to effectively drive transcription of key viral genes, specific enough to safely limit the viral replication largely to target tissues, and yet small enough to fit in the limited confines of an adenoviral genome. A primary obstacle, then, is discovering and defining TREs that fit the necessary characteristics.
Tissue-or tumor-specific TRE As the starting point for any transcriptionally regulated adenovirus, TREs naturally play a critical role in determining the tropism, potency, and specificity of the resultant virus. Therefore, the process of defining appropriate TREs is the central basis for design. The most straightforward method for the discovery and application of a TRE is classical 'promoter bashing' in which the regions upstream of genes are laboriously mapped and tested for core promoter, enhancers and silencers. In this approach, a tissue-or tumor-specific marker must first be identified, and the regulatory machinery for that marker must sufficiently and specifically regulate viral transcription upon application to the adenoviral backbone. When 'promoter bashing' fails to define such an element, transcriptional machinery can be manipulated to generate an appropriate TRE. The following examples illustrate some of the more established methods of TRE discovery.
One of the earliest TREs adapted for use in adenovirus-derived oncolytic viruses was identified from studying the tissue-specific expression of the widely used prostate cancer marker, PSA. Schuur et al. characterized the mechanism behind the tissue-specific expression of PSA based on previous observations that transcription of PSA is upregulated in response to binding by the steroid-complexed androgen receptor to consensusbinding sites called androgen response elements (Young et al., 1991 (Young et al., , 1992 Henttu et al., 1992; Schuur et al., 1996) . Characterization of the presumptive PSA promoter region for its ability to drive the activity of a reporter gene under androgen-positive conditions demonstrated minimal androgen responsiveness. However, incorporation of both the presumptive promoter region and the 5.3 kb sequence upstream of the PSA gene resulted in a three-to 50-fold induction of reporter gene activity (under androgen-positive conditions) compared to the promoter alone. Deletion analysis subsequently identified a minimal enhancer element that induced roughly the same level of reporter gene activity as the 'full-length' region, in a position and orientationindependent fashion. Induction of reporter gene activity by the minimal enhancer/promoter was examined in a variety of cell lines and found to maintain the tissuespecific profile initially witnessed with PSA expression. It is important to note, that the identification and design of the tissue-specific regulatory element described above was directed in large part by characterization of a previously identified transcriptionally upregulated serum marker.
A logical path of progression from the early work to characterize the promoter/enhancer elements for PSA is to identify TREs associated with transcriptional regulation of broadly applicable tumor markers such as the Rb/E2F and telomerase pathways. Based on observations that tumor suppression by pRb represses E2F-responsive promoter activity, Parr et al. reasoned that cellular loss of control over Rb function may also result in an increase in unbound, or 'free', E2F leading to an increase in E2F-dependent promoter activity (Adams and Kaelin, 1995; Sellers et al., 1995; Parr et al., 1997) . The E2F-1 promoter is among the known cellular promoters with consensus E2F-binding sites. Cloning the E2F-1 promoter (including each of the four E2F consensus-binding sites) into a replication-defective adenovirus/b-gal expression system and comparison to a similar, CMV-promoter driven b-gal expression system revealed a tumor-specific expression profile (Parr et al., 1997) . Injection of this vector into the brains of mice with established C6 glioma xenografts led to a b-gal staining pattern localized to the tumor as compared to the disseminated staining pattern of the control CMV promoter. The E2F-1 promoter may be activated in any cycling cell, healthy or diseased, raising a potential safety concern. E2F-driven b-gal reporter gene expression, however, was minimal compared to the CMV-driven control in the livers of mice that had recently undergone partial hepatectomies. Furthermore, mutation of the four consensus E2F-binding sites (abrogating E2F binding) resulted in constitutive activity from the mutant promoter strongly suggesting both repression and induction activities for the intact E2F-1 promoter. Given the potential for autoregulation of E2F expression by E2F-1, a tightly controlled mechanism of activity in healthy cells makes sense. These results suggest that the E2F-1 promoter is, in some respects, well suited for use as a tumor-specific TRE. They also illustrate the utility of 'promoter bashing' by progression from marker to tissue-specific TRE and finally to tumor-specific TRE.
In addition to tissue-or tumor-specific TREs readily adapted from the human genome, alternative methods have been used to define synthetic elements that fit the desired criteria for a given TRE. CTP1 is a composite TRE targeted to cells with upregulated expression of b-catenin, a trait common to many colorectal cancers (Lipinski et al., 2001) . In the transformation of healthy colorectal cells to a cancerous state, mutations to the adenomatous polyposis or CTNNB1 (b-catenin) genes lead to decreased phosphorylation of b-catenin thereby preventing its subsequent degradation by proteosomes (Bienz and Clevers, 2000; Polakis, 2000) . Since b-catenin binds TCF-4, the activity of promoters with TCFbinding sites is induced resulting in deregulated gene expression (Polakis, 2000) . Based upon the known cellular interactions of b-catenin with TCF-4, several TCF-binding sites were incorporated upstream of the minimal SV40 large T antigen promoter to generate CTP1. Characterization of promoter-dependent gene expression in a b-gal reporter system suggests that, in tumor biopsies, CTP1 activity is as high as the CMV promoter in target tissues. In peripheral primary tissue, however, CTP1 activity was highly attenuated relative to the CMV promoter, suggesting specific expression activity. More importantly, treatment of subcutaneous SW480 colon tumor xenografts with replication-defective adenovirus vectors expressing the Escherichia coli nitroreductase gene under the control of CTP1 or the CMV promoter led to similar antitumor efficacies. Yet a comparison of associated toxicities that might result from leakage of the prodrug-converting enzyme in a systemic fashion resulted in a pronounced lack of observed toxicity with CTP1 relative to the CMV promoter. The design of CTP1 has a certain elegance and serves as a demonstration of an alternative method to 'promoter bashing' by which to discover and apply TREs.
The minimal PSA enhancer/promoter, the E2F-1 promoter, and the CTP1 synthetic promoter serve as excellent examples of the basic tenets of discovering and utilizing TREs for tumor-or tissue-specific gene expression, although they are not necessarily exemplary models of TREs. The minimal PSA enhancer/promoter is very large and, relatively speaking, not particularly specific. The E2F-1 promoter is responsive to autoregulation, and its transcription factor is indirectly affected by adenoviral replication. Similarly, CTP1 also lacks some specificity and, in fact, has recently been supplanted by an improved composite element, CTP4. Furthermore, any such undertaking intended for use in a replicating virus must be approached with awareness of its possible unintended consequences. That said, once appropriate TREs are defined, the obstacle shifts to using them in a context where virus/host-cell interactions may impact the predicted function of the TRE. In short, TREs that test well in nonreplicating systems may not necessarily confer the same measured specificity and potency in a replicating adenovirus.
Approaches to generate transcriptionally controlled adenoviruses
A single TRE controlling a single adenoviral transcription unit
Using a TRE to control a key adenoviral transcription unit is very much akin to implementing a selective lossof-function mutation, one in which the loss-of-function extends to all cell types in which the heterologous element lacks for its complementary transactivators. Therefore, placing specific limits on the expression of one or more of the early region transcription units might result in little attenuation of the recombinant adenovirus in its target tumor or tissue type but significant attenuation in the less hospitable environment of normal or nontarget cells. Again, the E1a, E1b, and E4 proteins are among the most critical in the viral life cycle and abrogation of their expression in normal cells can be expected to result in something comparable to a crippling loss-of-function mutation, as well as a decrease in expression of the viral genes with E1a responsive promoter activity. Therefore, controlling E1a expression is a logical starting point by which to achieve transcriptional regulation of an adenovirus derivative.
Building on the tissue-specific expression profile of the minimal PSA enhancer/promoter described above, Rodriguez et al. (1997) inserted the element between the E1a promoter and the E1a coding region to create the adenoviral derivative CG7060 (also named CN706 or CV706). A control virus with a wild-type E1a region expressed approximately equal amounts of the E1a proteins in the tested PSA þ and PSA À cell lines (LNCaP and DU145, respectively). CG7060, however, expressed E1a in a fashion highly specific for PSA þ cells. Furthermore, replication of CG7060 was tissue specific and highly androgen dependent. Indeed, culturing CG7060 in the presence of a synthetic androgen led to a five-to sevenfold induction of viral replication. Finally, treatment of LNCaP and DU145 xenograft tumors in immune-deficient mice revealed a specific antitumor efficacy for the PSA-producing LNCaP tumor model.
As an early generation virus, CG7060 is validation for the ability of transcriptional regulation of key adenoviral genes to achieve tumor-or tissue-specific replication and lysis. This has also been demonstrated with recombinant adenoviral vectors in which other key early transcription units are under heterologous control. A key issue in cases of single TREs controlling single adenoviral transcription units is where to place the TRE. Owing to its crucial early role in the viral life cycle, the E1a unit is a logical starting point. As previously described, however, several of the early region units encode for proteins with functions similarly critical to the viral life cycle. With this in mind, viruses with either E1b or E4 under the heterologous transcriptional control of the minimal PSA enhancer/promoter have been developed. The oncolytic adenoviruses CV711 (heterologous control of E1b) and CV757 (heterologous control of E4) also replicated preferentially in PSA þ cells, indicating that specific replication can be achieved via transcriptional regulation of E1a, E1b, or E4 (Henderson and Yu, 2002) .
Regardless of which region is placed under heterologous transcriptional control, if a single unit is to be regulated, the need for the TRE to be tumor-or tissuespecific takes on an added measure of importance. As is the case with many biological systems, a degree of 'leakiness' might be expected. Given that these agents are routinely developed with an eye toward the clinic, a 'worst-case' scenario should be anticipated in which the unit under heterologous control partially escapes regulation allowing for a basal, or greater, level of transcription. Hitt and Graham (1990) have previously suggested that widely varying levels of E1a do not lead to significant differences in the ability of otherwise similar adenoviral vectors to replicate in HeLa cells. Such a finding comes with caveats, not the least of which is that such replication in tumor cells is not necessarily unexpected or undesirable. However, again, the intended clinical application of these viruses strongly suggests that 'worst-case' scenarios be considered.
A single TRE controlling multiple adenovirus transcription units
One way to mitigate the risk associated with having a single unit controlled by a single TRE is to place multiple units under the control of a TRE or TREs. Indeed, it follows quite readily that if specific replication can be achieved by artificially regulating expression of a single unit, specificity may be markedly enhanced by placing multiple units under artificial regulation. In essence, this is another force on the central theme of convergence of adenovirus replication and neoplastic transformation.
Internal ribosome entry sites (IRES) are a common mechanism by which many viruses utilize posttranscriptional modification to garner multiple proteins from a single transcript. Briefly, a polycistronic transcript is generated. Translation of the upstream cistron proceeds through standard initiation complexes. Secondary structures formed by the IRES assist in the entry of a ribosome at a location internal to the polycistronic transcript, leading to expression of the second cistron. By integrating a liver-specific TRE, the a-fetoprotein promoter and enhancer (AFP), in front of E1a and replacing the endogenous promoter of E1b with an encephalomyocarditis virus IRES, Li et al. (2001) generated CV840 and CV890 (E3 À and E3 þ , respectively). Specifically, the a-fetoprotein is normally expressed by fetal livers cells, the majority of hepatocellular carcinomas (HCCs), and regenerating cirrhotic livers. Therefore, vectors such as CV840 and CV890 may be expected to replicate and kill in an HCC-specific fashion. Indeed, CV840 and CV890 replicated preferentially in AFP þ tumor cells. Compared to a control virus, CV732, with just E1a under the transcriptional control of AFP, CV840 was attenuated 10-to 1000-fold in nontarget cell lines. Of note, use of the IRES resulted in alterations to the wild-type splicing patterns of both the upstream and downstream cistrons. This, however, did not compromise the replication of CV840 in AFP þ cell lines relative to a wild-type control. In general, use of the AFP TRE in concert with an IRES resulted in minimal attenuation but significant enhancements in specificity relative to the wild-type and AFP-only controls.
Multiple TREs controlling multiple viral transcription units
A more immediately apparent way to enhance the specificity of transcriptionally regulated adenoviruses is Oncolytic adenoviruses D Ko et al to place a second transcription unit under the control of a second TRE. For example, Ryan et al. (2004) described an oncolytic adenovirus, OAS403, in which the E1a and E4 transcription units are under the respective control of the E2F-1 and hTERT promoters. Compared to a single promoter control virus (E2F-E1a) with E1a under the control of the E2F-1 promoter, the cytotoxicity of OAS403 was only nominally attenuated relative to E2F-E1a. Furthermore, while the cytotoxicity of the single promoter control virus E2F-E1a in primary human hepatocytes was reduced compared to wild-type Ad5, OAS403 was attenuated to an even greater degree. In vivo toxicity studies of OAS403 administered intravenously to SCID mice at high dose (4 Â 10 12 vp/kg) led to a more modest decline in body weight, Bone-log higher levels of liver enzymes aspartate aminotransferase and alanine aminotransferase, and almost sevenfold less virus detected in livers than the control single promoter virus E2F-E3.
Likewise, Yu et al. (1999b) described CV764 in which E1a is driven by the minimal PSA enhancer and promoter and E1b is driven by a minimal enhancer and promoter element derived from the region upstream of the human kallikrein 2 gene. Comparisons of the replication of CG7060, CV764, and CV702 (recombinant wild-type Ad5 with a deletion in E3) in target and nontarget cells indicated significantly greater specificity for CV764. In the PSA þ cell line LNCaP, CG7060 and CV764 replication is minimally attenuated compared to CV702 (two-to threefold). In contrast, the replication of CG7060 is attenuated approximately 100-fold relative to CV702 in the PSA À lines HBL-100, OVCAR-3, SK-OV-3, and PA-1. Notably, CV764 replication is attenuated by as much as 5000-10 000-fold relative to CV702. These results suggest the use of multiple TREs to control multiple, essential viral genes can lead to greater specificity for the target tissue without further attenuation of viral replication.
Thus, selectively placing limits on the transcription of a key viral gene has clearly been validated as an effective strategy by which to control the replication of adenoviruses. Expanding that regulation to multiple transcription units has also been validated as a viable method by which to restrict viral replication to cells complementary via upregulation of a transcription factor, or what almost amounts to a selective loss-of-function mutation for the virus. However, the nature of the TRE or TREs, their points of insertion, and the quirks of modifying a complex biological system suggest that what can be generalized from one virus to the next may be limited.
Considerations for virus design
Adenoviruses have evolved a specific and coordinated gene expression pattern, presumably leading to efficient and robust propagation of the input virus. Manipulating this process to therapeutic ends is possible, but limited in that the life cycle of a recombinant virus may become so attenuated that mutations or homologous recombination events that restore robust replication could become likely. As discussed briefly above, the multitude of changes that have been attempted or could be made to engineer tumor-specific replication of adenoviruses each deserve consideration in their own right for their interactions with both the virus and the host cell. For example, application of a given TRE to different transcription units may affect the virus differently depending on the nature of the TRE and the level of expression of that unit required for robust viral replication. This is especially true of dual TRE strategies where wild-type levels of multiple proteins may be influenced by heterologous control. Furthermore, some modifications to the viral genome have been found to regularly facilitate imprecise recombination events. Finally, from a systemic standpoint, incorporation, or deletion of all or parts of the E3 region affects the ability of the virus to evade the host immune response. Taken together, the experience gained from the litany of tested modifications suggests very little in the way of set guidelines for virus design outside of the need to rationally consider and test each change to the genome for its potential consequences.
As the seminal modification of any transcriptionally regulated oncolytic adenovirus, the characteristics and nature of each TRE(s) can play a large role in determining the optimal position for integration into a given virus. For example, a weaker or less specific TRE may be more subject to the powerful promoter and enhancer elements contained within the left-hand side of the Ad genome (Osborne and Berk, 1983; Hoffmann et al., 2005) . Such TREs may be better applied to the E1b or E4 transcription units (Rubinchik et al., 2001) . For TREs that are tightly targeted to a very specific tissue-type and/or those that have considerable inherent strength, the presence of such upstream elements may be of little consequence. For those that are less tightly targeted or demonstrate lesser capacity to drive transcription of their respective transcription units, the effect may be considerable. Alternatively, Jakubczak et al. (2003) described the introduction of an SV40 polyA sequence to insulate the heterologous promoter from the upstream enhancer present in the left ITR. Still, such an insulator only partially addresses the more fundamental question of whether or not a TRE possesses the ideal characteristics for use at a particular position, or indeed at any position, in an oncolytic adenovirus. Overall, the nature of the TRE can have a far greater influence on the performance of the virus depending on its point of insertion.
In addition to site-related concerns, the use of multiple TREs has the potential to upset the coordinated expression of viral genes. Of concern is the possible disruption of a deliberate kinetic or stoichiometric relationship in which one gene is expressed at an earlier juncture or at a higher level than the other. For example, E1a expression leads to cellular toxicity and the activation of damage suppression mechanisms that are usually counteracted by expression of the E1b proteins. Similar complementary or inhibitory relationships exist between many of the early region proteins.
With viruses such as OAS403 and CV764, the presence of any heretofore unknown disruptions of these relationships has not led to a detectable, accompanying disruption to viral replication. This could be as a result of an inherent level of flexibility in requirements for each affected protein, or could indicate adequate complementation of function in the tested tumor models and cell lines. The potential, however, for a crippling disruption of a kinetic or stoichiometric relationship remains a possibility.
Virus/host cell interactions can also have a significant impact on the performance of a TRE, as well as inform the most ideal points for insertion. For example, binding of pRb by the E1a proteins leads to increased levels of 'free' E2F. With E2F-1 promoter-driven adenoviruses, 'free' E2F is expected to drive the expression of the E2F-1 promoter-linked transcription unit. When that unit is E1a, a positive feedback loop can be formed. Given an expectation of inherent initial 'leakiness' by the promoter, the effect of this series of interactions on the viral life cycle are difficult, at best, to predict. Loss of control over E1a expression could lead to a resultant increase in 'free' E2F, transcription of viral genes under E1a-responsive promoters, and the formation of E2F-E4 orf6/7 complexes resulting in E2 transcription (and downstream viral DNA replication). Therefore, the positive feedback mechanism of the E2F-1 promoter driving E1a can result in the loss of control over several transcription units. These concerns can be addressed in several different ways. With single promoter vectors, administration can be initially restricted to superficial or otherwise compartmentalized tumors so as to minimize any associated risk until they are better characterized. With dual TRE vectors, points of insertion for the TREs can limit the potential for escape transcription (such as with the transcriptional regulation of E1a and E4 in OAS403). In addition to transcriptional regulation, careful and deliberate abrogation of particular virus/ host cell interactions can add yet another layer of protection against escape transcription. For example, Onyx-411 is a dual TRE vector in which the E1a and E4 regions are under the transcriptional regulation of the aforementioned human E2F-1 promoter and a deletion has been made to the E1a CR2 region (Johnson et al., 2002) . E1a transcripts encoded with this deletion should be unable to encourage the accumulation of 'free' E2F thus mitigating the possibility of an autoregulatory feedback loop resulting from 'leaky' E1a transcription. In sum, the different natures of the TREs used in CV764, OAS403, and Onyx-411 capture the manner in which virus/host cell interactions can guide decisions on where to place TREs.
Another source of concern is the fine, very nebulous line between specific attenuation and crippling overengineering. In an attempt to further mitigate the potential for transcriptional read-through, the packaging signal (which overlaps with the enhancer elements of the E1a gene) was relocated from its native position adjacent to the left ITR to a position adjacent to the right ITR in some viruses (such as OAS403) (Ryan et al., 2004) . Rather than improve viral specificity, this change results in genetic instability wherein homologous recombination events are initiated that result in the return of the packaging signal to its native location along with the imprecise movement or excision of adjacent sequences (Li, unpublished data) . Similarly, the use of two identical TREs in a single adenoviral backbone (as in the case of Onyx-411) leads to homologous recombination of the viral backbone resulting in either self-inactivation of the virus or, worse, replicationcompetent recombinants of undetermined specificity (Shen, 2003) . Unintended recombination events have also been reported in a vector, CV716, with identical minimal PSA enhancer/promoters controlling E1a and E1b (Henderson and Yu, 2002) . In the course of pushing greater convergence of cancer and adenovirus-associated pathways in the hope of improving the oncolytic properties of adenoviral derivatives, it is imperative to consider the potential to push too far.
From a systemic standpoint, it is unclear whether inclusion of all or part of the E3 region is beneficial to the efficacy of replicating adenoviruses in tumor cells. Long considered dispensable for viral replication in vitro, more recent studies have suggested an important role for the E3 region, in vivo (Ilan et al., 1997; Yu et al., 1999a) . The E3 proteins function as modulators of the immune response and, in later stages of the viral life cycle, assist in host cell lysis and spread of progeny virions (Gooding et al., 1988 (Gooding et al., , 1991 Krajcsi and Wold, 1992; Hermiston et al., 1993; Tollefson et al., 1996; Lichtenstein et al., 2002 Lichtenstein et al., , 2004 . Therefore, deletion of some or all of these genes may result in an increased immune response that could enhance destruction of the tumor mass. Alternatively, the presence of some or all of the E3 genes may lead to greater replication of progeny virions in tumor cells prior to lysis, which could also result in enhanced destruction of the tumor mass. Indeed, in vivo studies suggest enhanced antitumor efficacy of E3-containing vectors (Yu et al., 1999a) . Without adequate models that can simulate the expected human immune response, however, it is difficult to determine the broader effects of the E3 region proteins in more complex systems.
While achieving greater specificity for target tissues will remain a priority for the development of transcriptionally regulated adenoviruses, adenoviruses have evolved over the course of time to most efficiently ensure their survival. Contemporary adenoviruses regulate the expression of their own genes and interact with the host cell in fashions that best suit their propagation. Transcriptional regulation of adenoviral replication is certainly a viable strategy by which to approach the development of therapeutics. However, if the resultant virus is too weak or its tropism too limited, its clinical utility will be compromised. Furthermore, the most clinically effective virus may not always be the most specific one. Again, the line between successful regulation of viral replication and crippling overengineering is difficult to define. Therefore, changes to the wild-type genome need to be balanced for the desired properties of the intended vector and the magnitude of disruption to the viral life cycle. That said, the nature of transcrip-tional regulation of adenoviruses allows for considerable flexibility to encourage the desired effect. TREs are a relatively modular property of the recombinant virus. Coupled with the options for their placement within the genome and the potentially complementary effect of incorporating multiple TREs, a flexible platform emerges that is adaptable to a broad array of applications.
Clinical development of transcriptionally controlled oncolytic adenoviruses
Solid theory and benchwork form the basis of any therapeutic development. However, the ultimate test is safety and performance in clinical trials. To date, selectively replicating oncolytic adenoviruses have advanced as far as a proposed Phase 3 trial in the United States and the completion of trials in China. As a subset, transcriptionally regulated oncolytic adenoviruses represent some of the more advanced candidates of the general platform. Therefore, the knowledge gained from these early trials can provide valuable insight as to how to best utilize such viruses in the near-term. (For an indepth discussion of the clinical results of the broader field of oncolytic viruses, readers are referred to Aghi and Martuza, 2005, this publication.) CG7060, with the minimal PSA enhancer/promoter driving E1a expression, has completed a Phase 1 trial in patients with locally recurrent prostate cancer following radiation therapy . The primary endpoint was treatment-related toxicity. However, antitumor activity was also evaluated. Patients were required to have a rising PSA level, indicating biochemical failure of the radiation therapy, and no evidence of metastases. In all, 20 men were treated by intraprostatic administration at a range of 1 Â 10 11 -1 Â 10 13 viral particles. The procedure was well tolerated with fever, chills, injection site pain, and hematuria being the most common side effects. Treatment with CG7060 was not associated with any alterations in liver function tests greater than grade 1. Detection of circulating copies of CG7060 in a delayed 'peak' suggested intraprostatic replication. Evidence of replication in the prostate tissue was further correlated by hexon staining, light microscopy, and electron microscopy. Dose-related decreases in serum PSA levels were seen, with several patients in the two highest dose groups exhibiting significant reductions.
Likewise, CG7870 (with the rat probasin promoter driving E1A, the minimal PSA enhancer/promoter driving E1B, and a wild-type E3 region) has been tested in patients with prostate cancer in Phase 1/2 studies (Small et al., 2002; DeWeese et al., 2003) . A Phase 1/2 trial of CG7870 in patients with locally recurrent prostate cancer with rising PSA levels following definitive external beam irradiation was initiated in 1999. The virus was administered under spinal anesthesia using a brachytherapy template and ultrasound 3D imaging with the MMS Terapac Plus 6.6 B3DTUI (Charlottesville, VA, USA) treatment planning software for implantation of radioactive seeds. Virus was initially administered in 0.1 ml aliquots from up to 40 brachytherapy needles.
A total of 20 patients were enrolled in this Phase 1/2 trial (DeWeese et al., 2003) . In all, 10 patients were treated at a dose level of 1 Â 10 12 viral particles, five patients at 3 Â 10 12 particles and five patients at 1 Â 10 13 particles. Treatment was well tolerated overall with no related serious adverse events. The most frequently reported adverse events were local injection site reactions, flu-like symptoms, and urinary tract symptoms consistent with the underlying disease process. One NCI-CTC treatment-related grade III adverse event occurred in a patient treated at the 1 Â 10 13 particle dose level. The patient had a grade III elevated D-dimer associated with grade II mild liver function test (LFT) elevations, which resolved in 29 days.
Patients were evaluable for PSA response if the baseline PSA value was greater than or equal to 5 ng/ml. The PSA value decreased 25-49% in eight of 12 evaluable patients (67%), and a decrease was observed in all patients at the highest dose cohort. With a median follow-up of approximately 6 months, 75% of evaluable patients remained progression-free; the median PSA progression-free survival has not been reached. No patient demonstrated a complete or partial response based on the prostate cancer working group criteria. These data indicate that intraprostatic administration of CG7870 is feasible and associated with an acceptable toxicity profile. The decrease in PSA levels observed in most evaluable patients after a single dose of CG7870 suggests biological antitumor activity for CG7870.
A second Phase 1/2 trial of intravenous CG7870 was conducted in patients with hormone refractory metastatic prostate cancer (Small et al., 2002) . In all, 23 patients were treated, each with a single intravenous bolus of CG7870 at doses of 1 Â 10 10 -6 Â 10 12 viral particles (three patients per dose level except two at 6 Â 10 12 vp). Overall, CG7870 was well tolerated at all dose levels. The major toxicity experienced, besides flulike symptoms (fever, fatigue, rigors, nausea, and vomiting) associated with intravenous infusion, was a transient, mild-to-moderate elevation of LFTs, and a transient, nonclinically significant coagulopathy in a minority of patients. Pharmacokinetic investigations revealed peak virus levels within the first hour after injection with a rapid clearance from the blood; a secondary peak indicative of in vivo replication is seen in most patients beginning about 3 days after administration. Stabilization of PSA was seen in 6/23 (26%) patients (median duration 4 months) and o50% declines of PSA were observed in 3/23 (13%) patients. This preliminary data indicates that a single intravenous dose of CG7870 was safe and associated with anti-PSA activity at the doses administered.
While safety profiles have been encouraging, the biological activity demonstrated in early clinical stage viruses is clearly not significant enough to support use as standalone treatments. Therefore, oncolytic adenoviruses are being employed in combination with traditional therapeutics in the hope of improving efficacy. Early evidence, such as preclinical evaluation of CG7060 and CG7870 in combination with conventional therapeutics, suggests the possibility of synergistic activity for oncolytic viruses in concert with established treatments. In vivo studies of the human prostate cancer xenograft LNCaP in mice demonstrated a synergistic effect between radiation and CG7060 or CG7870 Dilley et al., 2005) . Administration of 1 Â 10 7 viral particles/mm 3 (50-fold lower compared to monotherapy) and 10 Gy of single fraction local tumor radiation increased necrosis by 180 and 690%, apoptosis by 330 and 880%, and decreased blood vessel number by 1290 and 600%, respectively, compared to the same dose of CG7060 or radiation alone . Mechanistic possibilities for this include increased viral replication resulting from treatment with radiation or chemotherapy along with augmentation of the antitumor activity of radiation or chemotherapy by virusinduced p53-dependent and independent apoptosis. Of particular note is the lack of increase in toxicity following combined treatment as compared with CG7060 or radiation alone. CG7870 was also synergistic in combination with a variety of chemotherapeutic agents. For example, the dose of CG7870 required for complete remission of LNCaP prostate xenografts in immune-deficient mice when used in combination with docetaxel is 1000-fold lower than that of the viral monotherapy, significantly increasing the therapeutic index . Furthermore, less toxicity, as characterized by body weight, was observed in the combination treatment group compared to groups treated with either agent alone. These studies, taken in the context of the clinical results seen with Onyx-015 in combination with 5-fluorouracil and cisplatin, warrant further clinical investigations of the possible applications of oncolytic viruses in concert with traditional therapies (Khuri et al., 2000) .
Based on the early results of CG7870 and other oncolytic adenoviruses in combination therapies, new clinical protocols are actively enrolling patients. Currently, intravenously administered CG7870 in combination with docetaxel in chemotherapy-naı¨ve patients with metastatic hormone-refractory prostate cancer is being evaluated for the maximum-tolerated dose and safety of the combination treatment.
These early trials have provided valuable insight as to how to best apply the current generation of viruses in the short term as well as insight into what can be improved in the next generation of viruses. Perhaps most notable is the safety profile achieved with the tested viruses. And while, at present, the biological activity of monotherapy does not warrant use as a standalone treatment, the evidence of synergistic activity suggests oncolytic adenoviruses in combination with chemotherapy or radiation hold promise for the near future. Additionally, the promise of multimodal therapies indicates that one of the most promising avenues for development of oncolytic adenoviruses is to take advantage of this class of agent's unique ability to carry transgenes that can attack different cancers with mechanisms of action complementary to virus-mediated effects. Taken together, the clinical lessons as well as expanding knowledge of the biology of adenoviruses and cancer can serve as guides for the immediate and longer-term development of oncolytic adenoviruses.
Future directions
Beyond the short-term clinical uses of today's transcriptionally regulated adenoviruses, a number of steps can be taken to improve the potential curative effects of oncolytic adenoviruses. The inherent specificity of the therapy makes it an ideal platform from which to deliver transgenes that can enhance the lytic effect of the virus, complement activity by allowing multiple cellular pathways to be targeted, and/or mediate antitumor activity that escapes the purview of capabilities possessed by a simple virus backbone. Moreover, the detargeting and retargeting of the natural capsid/receptor-mediated tropism of the wild-type Ad5 serotype may yet introduce an additional layer of specificity to replicating adenoviral systems and at the very least result in the delivery of more input virus to the target site. Finally, a larger pool of knowledge concerning adenovirus biology in the context of oncolytic applications and more robust, rapid analytical systems can serve to guide researchers as to how to best tailor each new therapy to achieve desired effects. As a whole or piecemeal, such advancements stand to enhance the potential curative effects of oncolytic adenoviruses.
Most cancer treatment regimens consist of multimodal therapies. Since cancers are by their nature differentiated and adept at survival, attacking cancers via multiple mechanisms improves the odds of achieving complete destruction of all malignant cells. Oncolytic viruses and chemotherapy-conjugated antibodies have the unique ability to mediate multimodal antitumor activity with a single agent. Therefore, to enhance the oncolytic effect, viruses are actively being 'armed' with additional genes that can mediate a bystander effect. Such genes can fall into any number of classes including prodrug-converting enzymes, chemosensitizers, cytokines, tumor suppressors, proapoptotic, cytolysins, antiangiogenic, etc. The particular challenges associated with 'arming' replicating adenoviruses are defined by the limited space of the Ad genome, balancing the anticancer effect of transgenes against possible antiviral effects, and preserving the safety profile achieved with unarmed oncolytic vectors.
To date, the most clinically advanced adenovirusbased vectors armed with transgenes have been of the nonreplicating variety. Already, a p53-armed, nonreplicating adenovirus vector has won regulatory approval in China. A rolling Biologics License Application for a similar product has been initiated in the United States. Additionally, several nonreplicating vectors expressing transgenes are being tested in Phase 1/2 trials. With respect to selectively replicating adenoviruses, a virus similar to Onyx-015 but armed with the prodrugconverting enzymes cytosine deaminase and thymidine kinase has completed two Phase 1 trials (Freytag et al., 2002 (Freytag et al., , 2003 .
Given this relative success, it stands to reason that appropriate arming of a transcriptionally regulated oncolytic adenovirus holds similar or possibly even greater potential. Recently, a series of granulocyte macrophage-colony-stimulating factor (GM-CSF) armed oncolytic adenoviruses have been described in which transgene expression was tied to viral replication (Bristol et al., 2003; Zhu et al., 2005) . Already, a similar virus (CG0070) has been described that has entered clinical trials for the treatment of recurrent bladder cancer (Ramesh et al, 2005) . Similarly, VRX-009 is an armed oncolytic adenovirus in which the adenovirus death protein (ADP) gene is overexpressed as a function of viral replication . With both the GM-CSF armed viruses and VRX-009, transgene expression has been successfully linked to viral replication adding a significant level of safety for more toxic genes. Furthermore, the use of prodrug-converting enzymes, chemosensitizers, or immunostimulants may expand the reach of the current generation of oncolytic adenoviruses beyond local therapies to generate regional or even systemic antitumor effects.
Expanding the scope of oncolytic adenoviruses from local to systemic therapies can be significantly advanced by altering or coating the adenovirus capsid proteins as a way to detarget, retarget, and/or bypass host immune reactions. Part of the lack of potency of intravenously delivered oncolytic adenoviruses is tied to the significant antigenic properties and broad infectivity of the Ad5-based platform. With intravenous administration, the majority of viral particles are taken up by the Kupffer cells of the liver (Worgall et al., 1997) . Furthermore, Ad5 normally enters cells through the ubiquitous CAR receptor meaning additional quantities of virus will end up transducing healthy cells as opposed to the target tumor tissues. Finally, it has been found that low CAR expression in tumor cells can hinder the efficacy of oncolytic adenoviruses (Cripe et al., 2001; Douglas et al., 2001) . To address these limitations, the viral capsid can be masked and/or modified. Retargeting of vectors is proceeding by both genetic and chemical modification such as swapping of fiber, shaft, and knob proteins from other adenovirus serotypes, substitution of binding motifs, and conjugation to tissue-or tumorspecific targeting ligands (Dmitriev et al., 1998; Cripe et al., 2001; Douglas et al., 2001; Hemminki et al., 2001; Shayakhmetov et al., 2005) . Alternatively, to abrogate absorption of vector particles during pass-through of the liver, vector capsids are being chemically modified to prevent nonspecific uptake by immune cells (Fisher et al., 2001; Green et al., 2004) . To date, detargeting by genetic or chemical means has proven to be more readily achieved than retargeting. That is, viruses have been developed which successfully bypass much of the absorption by the liver and/or are no longer subject to CAR-mediated entry (Fisher et al., 2001; Green et al., 2004) . High-efficiency transduction by those viruses of their new target receptors has proven more elusive. While progress has been made, consistent chemical coating of adenovirus capsids and conjugation with or without tissue-specific ligands remains a challenge. That said, successful genetic and/or chemical modification of adenoviral capsids has the potential to increase the efficacy of the agent, improve its specificity, add an additional safety mechanism, and expand the scope of the agent from local to systemic therapy.
Long-term development of oncolytic adenoviruses, then, may incorporate changes determined in a deliberate and rational fashion to be beneficial to the ultimate goal of safe, targeted transcriptionally regulated adenoviruses capable of potent treatment of cancers through multiple modalities. In order to facilitate that goal, a number of steps can be taken in the near-term that may aid in the process. Reflective and accurate in vitro and in vivo analysis can save considerable time in development cycles by allowing limitations in virus design or strategy to be discovered and corrected at earlier stages. Currently, owing to the poor replication of human adenoviruses in murine cells, in vivo tumor models are limited by the need to use nude or SCID mice with established human tumor xenografts. As a result of the robust immune response to adenovirus in immune competent animals, the predictive value of these immune deficient systems for eventual clinical experience is limited. Coupled with advancing knowledge of adenovirus and cancer cell biology, more specific analytical systems can shorten the learning curve involved in virus design and allow for a greater number of, but better considered, alterations to virus design. For example, the arming of oncolytic adenoviruses with transgenes is complicated by the activity of the many viral proteins that may have a countervailing effect to the intended use of the transgene. Robust analytical systems can provide more rapid, accurate insight into such effects or those of abrogating expression of individual viral genes. Ultimately, incorporation of those enhancements deemed most beneficial and the stepwise evaluation of both the global and virus-specific effects of each additional change holds the possibility of bringing forth more potent, safe oncolytic adenoviruses suitable for broad applications as anticancer therapeutics.
In sum, the longer-term potential of oncolytic adenoviruses rests in arming, targeting and expanded knowledge of adenovirus and cancer biology. The inherent specificity of this class of agents makes them well suited to deliver transgenes that can complement virus-mediated antitumor activity by allowing multiple cellular pathways to be targeted. In addition to arming, the detargeting and retargeting of the receptor/capsidmediated tropism of Ad5 has the potential to add another layer of safety and expand the scope of applications for the platform. Coupled with greater experience in therapeutic applications of oncolytic adenoviruses and better analytical systems, such advancements may yet expand the role of oncolytic adenoviruses in treatment regimens.
Conclusion
The mechanisms of neoplasia and virus-mediated transformation of healthy cells often result in a 
